Phase 2 N=11 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma
Adrenocortical Carcinoma · Peritoneal Carcinomatosis
Primary: Intraperitoneal Progression Free Survival (PFS) — 19 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=282 Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
Metabolism and Nutrition Disorder · Obesity
Primary: Change in Body Weight (%) — -7.4; -4.0; -9.1; -4.8 percent change — p=0.0003
Phase 2 N=50 SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients
N/A N=91 Intrapartum Epidural Catheter Displacement: Dressing Methods
Analgesia, Obstetrical
Primary: Epidural Catheter Migration — 44; 25; 17 percentage patients catheter migration
Phase 2 N=10 An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
Papulopustular Rosacea
Primary: Facial Erythema — 6.6; 6 score on a scale
Phase 4 N=42 Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
Smoking Cessation · Schizophrenia
Primary: Exhaled Carbon Monoxide (CO) as Parts Per Million (PPM) — 11.5; 12.3; 12.0; 7.8 ppm
Phase 2 N=60 Eltrombopag for Post Transplant Thrombocytopenia
Thrombocytopenia
Primary: Comparing the Efficacy of Eltrombopaq and Placebo — 15; 5; 9; 0 Participants
N/A N=24 Aerosolized Albuterol Use in Severe BPD
Severe Bronchopulmonary Dysplasia
Primary: Change in Expiratory Flow Between Pre and Post-medication Dosing — 0.38; 0.70; 0.45 L/min
Phase 2 N=74 A Phase I/II Trial of Stereotactic Body Radiation Therapy
Inoperable Stage I/II Non-small Cell Lung Cancer
Primary: Phase I Portion Only: Determine the Maximum Tolerated Dose of SBRT — 11 Gy x 5 fractions
Phase 2 N=193 Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults
Malaria Vaccine
Primary: Number of Participants Who Experience a Serious Adverse Events (SAEs) 29 Days After the Last Vaccination — 1; 0; 0; 1 Participants
Phase 1 N=6 A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants
Healthy Volunteers
Primary: Cumulative Percentage of Administered Radioactivity Recovered in Urine — 55.4; 56.8; 55.1 percentage of radioactive dose
Phase 2 N=1,198 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
Dengue Fever · Dengue Hemorrhagic Fever · Dengue Virus
Primary: Percentage of All Participants Reporting Solicited Injection-site and Systemic Reactions Following Each Injection With CYD Dengue Vaccine or Placebo — 53.9; 66.7; 1.0…
N/A N=30 Exercise Detection Study
Type 1 Diabetes
Primary: Mean Change in Sensor Glucose in Subjects With Type 1 Diabetes — -26.4; 12.0 mg/dL
N/A N=8,584 Low Indexes of Metabolism - Information to Teams (LIMIT)
Weight Loss · Thinness · Malnutrition
Primary: Death From Any Cause — 285; 245 Participants
N/A N=6 Intervention to Reduce Sedentary Time
Mild Cognitive Impairment
Primary: Change in Average Daily Sitting Time — 0.43; 0.98 minutes per day